Drugs / Tilelizumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04992143 | Aug 2021 → Aug 2023 | hepatocellular carcinoma | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04997837 | Jul 2021 → Jul 2027 expected | gastric cancer | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilelizumab | “Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.” NCT04997837 ↗ |
| Route | Intravenous | “Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE” NCT04992143 ↗ |